| # | Title | Journal | Year | Citations |
|---|
| 1 | A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer | Clinical Colorectal Cancer | 2015 | 391 |
| 2 | Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality | Clinical Colorectal Cancer | 2016 | 268 |
| 3 | Bowel Function 14 Years After Preoperative Short-Course Radiotherapy and Total Mesorectal Excision for Rectal Cancer: Report of a Multicenter Randomized Trial | Clinical Colorectal Cancer | 2015 | 231 |
| 4 | Changing Patterns of Bone and Brain Metastases in Patients with Colorectal Cancer | Clinical Colorectal Cancer | 2005 | 186 |
| 5 | Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2006 | 169 |
| 6 | Clinical Management of Oxaliplatin-Associated Neurotoxicity | Clinical Colorectal Cancer | 2005 | 163 |
| 7 | Dihydropyrimidine Dehydrogenase Deficiency, a Pharmacogenetic Syndrome Associated with Potentially Life-Threatening Toxicity Following 5-Fluorouracil Administration | Clinical Colorectal Cancer | 2004 | 152 |
| 8 | Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone | Clinical Colorectal Cancer | 2008 | 147 |
| 9 | Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2006 | 141 |
| 10 | Integrating the Anti–VEGF-A Humanized Monoclonal Antibody Bevacizumab with Chemotherapy in Advanced Colorectal Cancer | Clinical Colorectal Cancer | 2004 | 131 |
| 11 | Sensitivity and Specificity of a Stool DNA Multitarget Assay Panel for the Detection of Advanced Colorectal Neoplasia | Clinical Colorectal Cancer | 2003 | 130 |
| 12 | Prognostic Significance of miR-215 in Colon Cancer | Clinical Colorectal Cancer | 2011 | 122 |
| 13 | An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2012 | 117 |
| 14 | Early-onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer | Clinical Colorectal Cancer | 2017 | 117 |
| 15 | Thymidylate Synthase: A Critical Target for Cancer Chemotherapy | Clinical Colorectal Cancer | 2002 | 115 |
| 16 | Liver Resection for Metastatic Colorectal Cancer in the Age of Neoadjuvant Chemotherapy and Bevacizumab | Clinical Colorectal Cancer | 2006 | 115 |
| 17 | Endorectal Ultrasound in the Preoperative Evaluation of Rectal Cancer | Clinical Colorectal Cancer | 2004 | 112 |
| 18 | Brain Metastases from Colorectal Cancer: Risk Factors, Incidence, and the Possible Role of Chemokines | Clinical Colorectal Cancer | 2009 | 112 |
| 19 | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis | Clinical Colorectal Cancer | 2017 | 110 |
| 20 | Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer | Clinical Colorectal Cancer | 2014 | 108 |
| 21 | Epidermal Growth Factor Receptor as a Therapeutic Target in Colorectal Cancer | Clinical Colorectal Cancer | 2003 | 107 |
| 22 | Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer | Clinical Colorectal Cancer | 2005 | 107 |
| 23 | The Role of Src in Colon Cancer and Its Therapeutic Implications | Clinical Colorectal Cancer | 2014 | 106 |
| 24 | Clinical Significance of Long Intergenic Noncoding RNA-p21 in Colorectal Cancer | Clinical Colorectal Cancer | 2013 | 104 |
| 25 | Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber | Clinical Colorectal Cancer | 2018 | 102 |
| 26 | Cetuximab-Induced Hypomagnesemia in Patients with Colorectal Cancer | Clinical Colorectal Cancer | 2006 | 101 |
| 27 | Rising Proportion of Young Individuals With Rectal and Colon Cancer | Clinical Colorectal Cancer | 2019 | 100 |
| 28 | SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2015 | 98 |
| 29 | Colorectal Cancer Initial Diagnosis: Screening Colonoscopy, Diagnostic Colonoscopy, or Emergent Surgery, and Tumor Stage and Size at Initial Presentation | Clinical Colorectal Cancer | 2016 | 96 |
| 30 | Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2007 | 95 |
| 31 | Portal Hypertension Associated With Oxaliplatin Administration: Clinical Manifestations of Hepatic Sinusoidal Injury | Clinical Colorectal Cancer | 2009 | 94 |
| 32 | CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer | Clinical Colorectal Cancer | 2014 | 94 |
| 33 | Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis | Clinical Colorectal Cancer | 2016 | 94 |
| 34 | Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer? | Clinical Colorectal Cancer | 2017 | 94 |
| 35 | Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer | Clinical Colorectal Cancer | 2008 | 90 |
| 36 | A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer | Clinical Colorectal Cancer | 2011 | 90 |
| 37 | Molecular Tests for Colorectal Cancer Screening | Clinical Colorectal Cancer | 2011 | 90 |
| 38 | Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials | Clinical Colorectal Cancer | 2015 | 90 |
| 39 | Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management | Clinical Colorectal Cancer | 2018 | 90 |
| 40 | The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer | Clinical Colorectal Cancer | 2017 | 89 |
| 41 | Optimal Interval to Surgery After Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Systematic Review and Meta-analysis | Clinical Colorectal Cancer | 2018 | 88 |
| 42 | PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2012 | 87 |
| 43 | Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer | Clinical Colorectal Cancer | 2012 | 84 |
| 44 | Thymidylate Synthase Pharmacogenetics in Colorectal Cancer | Clinical Colorectal Cancer | 2001 | 83 |
| 45 | Use of Soluble Recombinant Decoy Receptor Vascular Endothelial Growth Factor Trap (VEGF Trap) to Inhibit Vascular Endothelial Growth Factor Activity | Clinical Colorectal Cancer | 2004 | 81 |
| 46 | Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer? | Clinical Colorectal Cancer | 2011 | 78 |
| 47 | Treatment of Pulmonary Colorectal Metastases by Radiofrequency Ablation | Clinical Colorectal Cancer | 2013 | 76 |
| 48 | Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope? | Clinical Colorectal Cancer | 2010 | 75 |
| 49 | Expression of the Antiapoptotic Protein Survivin in Colon Cancer | Clinical Colorectal Cancer | 2011 | 74 |
| 50 | The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy | Clinical Colorectal Cancer | 2016 | 73 |
